Laureate Enters Into Contract With ZZ Biotech

Laureate Pharma has entered into a development and manufacturing agreement with ZZ Biotech. As per the agreement, Laureate will produce activated protein C variant under cGMP conditions.

Robert Broeze, president & CEO of Laureate, said: “We are pleased that ZZ Biotech has chosen Laureate as their manufacturing partner. We will work closely with the ZZ Biotech team and help them drive their product from development into the clinic.”

Berislav Zlokovic, founder and chief scientific officer of ZZ Biotech, Dean’s professor and director center for Neurodegenerative and Vascular Brain Disorders at the University of Rochester, NY, said: “Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-scale grade materials. This agreement enables us to operationally leverage Laureate’s expertise and infrastructure while we seek to establish new treatment for stroke and neurodegenerative disorders.”

Laureate Pharma offers bioprocessing services that accelerate new products from development through production. Laureate provides specialised services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products.

ZZ Biotech develops new therapies for the aging and damaged brain, including those affected by stroke and other neurodegenerative disorders.